Simultaneous co-assembly of fenofibrate and ketoprofen peptide for the dual-targeted treatment of nonalcoholic fatty liver disease (NAFLD).,Chemical Communications

当前位置： X-MOL 学术 › Chem. Commun. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Simultaneous co-assembly of fenofibrate and ketoprofen peptide for the dual-targeted treatment of nonalcoholic fatty liver disease (NAFLD).
Chemical Communications ( IF 4.3 ) Pub Date : 2020-04-02 , DOI: 10.1039/d0cc00513d
Zhongyan Wang ₁ , Chuanrui Ma , Yuna Shang , Lijun Yang , Jing Zhang , Cuihong Yang , Chunhua Ren , Jinjian Liu , Guanwei Fan , Jianfeng Liu

Affiliation

We have developed a co-assembled nanosystem based on fenofibrate and ketoprofen by tactfully utilizing their simultaneous benzophenone interaction, which greatly enhances the bioavailability of fenofibrate and plays a role in the dual-targeted treatment of NAFLD by reducing hepatic lipid accumulation and inflammatory responses.

中文翻译：